Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Adcetris | Brentuximab vedotin | Hodgkin Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Rebif | Interferon beta-1a | Clinically isolated syndrome | Do not list | Complete | ||
Jentadueto | Linagliptin-metformin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
Afinitor | Everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | Do not list | Complete | ||
Fycompa | Perampanel | Epilepsy, partial onset seizures | List with criteria/condition | Complete | ||
Edarbi | Azilsartan medoxomil | Hypertension | Do not list at the submitted price | Complete | ||
Edarbyclor | Azilsartan medoxomil + chlorthalidone | Hypertension | Do not list | Complete | ||
Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | |||
Sublinox | Zolpidem tartrate | Insomnia | Do not list | Complete | ||
Xtandi | Enzalutamide | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete |